Subscribe to RSS
Download PDF
DOI: 10.1055/s-0037-1614521
Haemostatic Abnormalities, Cardiac Involvement and Serum Tumor Necrosis Factor Levels in X-linked Dystrophic Patients
Authors
Publication History
Received
03 September 1998
Accepted after revision
10 December 1998
Publication Date:
09 December 2017 (online)
Summary
Left ventricular thrombosis and systemic emboli have been demonstrated to complicate cardiomyopathy in Duchenne and Becker muscular dystrophy (DMD, BMD). We investigated plasma levels of pro-thrombin fragment 1+2 (F1+2), thrombin-antithrombin III complex (TAT) and circulating levels of tumor necrosis factor-α (TNF-α), a pro-coagulant cytokine that has been shown to be elevated in patients with depressed cardiac function, in 20 patients with DMD and 12 patients with BMD as compared with 30 age-matched control subjects. Significantly elevated levels of F1+2 (DMD: 1.4 ± 0.8 nmol/l; BMD: 1.8 ± 0.8 nmol/l vs. controls: 0.7 ± 0.2 nmol/l, p <0.01 and p <0.001, respectively), TAT complexes (DMD: 4.7 ± 2.7 αg/l, BMD: 5 ± 2.3 αg/l vs. controls: 1.6 ± 0.5 αg/l, p <0.001) and TNF-α (54 ± 9 vs. 25 ± 7 pg/ml, p <0.001) were observed in patients with the dystrophic disease compared to control subjects. A significantly negative correlation was also found between F1+2 and TAT complexes and left ventricular ejection fraction (r = –0.65, p <0.0001; r = –0.80, p <0.0001, respectively) and a positive correlation between F1+2 and TAT complexes and serum TNF-α levels (r = 0.67, p <0.0001; r = 0.70, p <0.0001, respectively). Our results indicate a hypercoagulable state in X-linked dystrophic patients. A possible relationship between haemostatic activation, left ventricular dysfunction and TNF-α system upregulation may be suggested.
-
References
- 1 Perloff JK. Neurological disorders and heart disease. In Heart Disease, A Textbook of Cardiovascular Medicine. Brauwald E. eds W. B.: Saunders Company; 1997: 1865-913.
- 2 Berko BA, Swift M. X-linked dilated cadiomyopathy. N Engl J Med 1987; 316: 1186-91.
- 3 Melacini P, Fanin M, Danieli GA, Fasoli G, Villanova C, Angelini C, Vitiello L, Miorelli M, Buja GF, Mostacciuolo ML, Pegoraro E, Dalla Volta S. Cardiac Involvement in Becker muscular dystrophy. J Am Coll Cardiol 1993; 22: 1927-34.
- 4 Melacini P, Vianello A, Villanova C, Fanin M, Miorin M, Angelini C, Dalla Volta S. Cardiac and respiratory involvement in advanced stage Duchenne Muscular Dystrophy. Neuromusc Disord 1996; 6: 367-76.
- 5 Hoogerwaard ED, de Voogt WG, Wilde AAM, van der Wouw PA, Bakker E, van Ommen G-J B, de Visser M. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. J Neurol 1997; 244: 657-63.
- 6 Orlov YSK, Brodsky MA, Allen BJ, Ott RA, Orlov MV, Jay CA. Cardiac manifestations and their management in Becker’ muscular dystrophy. Am Heart J 1994; 128: 193-6.
- 7 Rubler S, Perloff J, Roberts W. Clinical pathological conference: Duchenne’s muscular dystrophy. Am Heart J 1977; 94: 776-84.
- 8 Frankel K, Rosser R. The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Human pathology 1976; 7: 375-86.
- 9 Riggs T. Cardiomyopathy and pulmonary emboli in terminal Duchenne’s muscular dystrophy. Am Heart J 1990; 119: 690-3.
- 10 Gaffney JF, Kingston WJ, Metlay LA, Gramiak R. Left ventricular thrombus and systemic emboli complicating the cardiomyopathy of Duchenne’s muscular dystrophy. Arch Neurol 1989; 46: 1249-52.
- 11 Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognising the role of proinflamatory cytokines. Chest 1994; 105: 897-904.
- 12 Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure. Circulation 1995; 92: 1379-82.
- 13 Torre-Amione G, Kapadia S, Lee J, Durand J-B, Bies RD, Young JB, Mann DL. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-11.
- 14 ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJH. Cyto-kines: triggers of clinical thrombotic disease. Thromb Haemost 1997; 78: 415-9.
- 15 Vignos PJ. Watkins MP. The effect of exercise in muscular dystrophy. JAMA 1966; 197: 843-8.
- 16 Schiller NB. Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of The American Society of Echocardiography. Circulation 1991; 84: 280-7.
- 17 Gardin JM, Dabestani A, Takenaka K, Rohan MK, Knoll M, Russell D, Henry WL. Effect of imaging view and sample volume location on evaluation of mitral flow velocity by pulsed Doppler echocardiography. Am J Cardiol 1986; 57: 1335-9.
- 18 Amiral J, Fareed J. Thromboembolic disease: biochemical mechanisms and new possibilities of biological diagnosis. Sem Thromb Haemostas 1996; 22: 41-8.
- 19 Falk RH, Foster E, Coats MH. Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective follow-up study. Am Heart J 1992; 123: 136-42.
- 20 Jafri SM. Hypercoagulability in heart failure. Sem Thromb Haemostas 1997; 23: 543-5.
- 21 Joung SC, Wilensky RL, Zeller J, Sawada S. Thrombin activation in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21 Suppl A 311A.
- 22 Nigro G. Cardiac involvement in neuromuscular diseases. In Handbook of Autonomic Nervous System Dysfunction. Korczyn AD. eds. Marcel Dekker, Inc: 1995: 179-202.
- 23 Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
- 24 Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H. Increased of serum neopterin and decreased production of neutrophil super-oxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993; 22: 1897-901.
- 25 Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92: 1479-86.
- 26 Testa M, Yeh M, Leee P, Fanelli R, Loperfido F, Berman JW, Lejemtel TH. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28: 964-71.
- 27 Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, Cornelio F, Morandi L, Mantegazza R. Expression of transforming growth factor β1 in dystrophic patients muscles correlates with fibrosis. J Clin Invest 1995; 96: 1137-44.
- 28 Tews DS, Goebel HH. Cytokines expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996; 55: 342-7.
- 29 Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995 1995; 63: 9-16.
- 30 Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 31: 749-53.
- 31 Koniaris LS, Goldhaber SZ. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol 1998; 31: 745-8.